Docencia
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies (15-02-2018)
Dra. Matilde Sánchez Conde. Infectious Diseases Unit. Hospital Ramón y Cajal, Madrid
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance ofHIV viral suppression in patients with high cardiovascular (01-02-2018)
Dr. Esteban Martínez. Infectious Diseases Unit. Hospital Clínic, University of Barcelona
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review andmeta-regression analysis (18-01-2018)
Dr. Arkaitz Imaz. Servicio de Enfermedades Infecciosas Hospital Universitario de Bellvitge, Barcelona
Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older (01-01-2018)
Dr. Ana Mariño. Unidad de VIH del Hospital Arquitecto Marcide-Novoa Santos
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, noninferiority trial (15-12-2017)
Dr. Julián Olalla Sierra. Especialista en Medicina Interna Hospital Costa del Sol, Marbella
Antiretroviral combination use during pregnancy and the risk of major congenital malformations (01-12-2017)
Dra. Marta Montero Alonso. Unidad de Enfermedades Infecciosas Hospital Universitario y Politécnico la Fe, Valencia
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study (16-11-2017)
Dra. Matilde Sánchez Conde. Infectious Diseases Unit Hospital Ramón y Cajal, Madrid
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of randomised, open-label, phase 2b, non-inferiority trial (02-11-2017)
Dr. Arkaitz Imaz. Infectious Diseases Unit Hospital de Bellvitge, Barcelona
Tolerability of Integrase Inhibitors in a Real-Life Setting (16-10-2017)
Dr. Esteban Martínez. Infectious Diseases Unit Hospital Clínic, University of Barcelona
Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort (02-10-2017)
Dra. Ana Mariño. Unidad de VIH Hospital Arquitecto Marcide-Novoa Santos
Single Dose Versus 3 Doses of Intramuscular Benzathine Penicillin for Early Syphilis in HIV: A Randomized Clinical Trial (15-06-2017)
Dr. Adrian Currán Atencion sanitaria y hospitalaria Hospital Universitari de la Vall d´Hebron
HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers (01-06-2017)
Dr. José Ramón Blanco. Investigador de la Unidad de VIH y Alteraciones Metabólicas Asociadas. Centro de investigación Biomédica de La Rioja
Eradication of HCV and non–liver-related non–AIDS-related events in HIV/HCV coinfection (16-05-2017)
Dra. Marisa Montes. Unidad de enfermedades infecciosas. Hospital Universitario de la Paz
Ischaemic stroke in HIV-infected pa:ents: a case–control study (28-04-2017)
Dr. Javier de la Torre Lima. Servicio de Medicina Interna. Hospital Costa del Sol. Marbella
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population (17-04-2017)
Dra. Concha Amador Prous. Médico de Enfermedades Infecciosas. Hospital Villajoyosa de Alicante
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial (31-03-2017)
Dr. José A. Pérez Molina. Servicio de Enfermedades Infecciosas. Hospital Universitario Ramón y Cajal
High Rates of Anal High-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Who Do Not Meet Screening Guidelines (15-03-2017)
Dr. Adrian Currán Atencion sanitaria y hospitalaria Hospital Universitari de la Vall d´Hebron
Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study (01-03-2017)
Dr. José Ramón Blanco. Investigador de la Unidad de VIH y Alteraciones Metabólicas Asociadas. Centro de investigación Biomédica de La Rioja
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention (15-02-2017)
Dra. Marisa Montes. Unidad de enfermedades infecciosas. Hospital Universitario de la Paz. Madrid
